The company expects 2023 net sales to be in the range of $290 million to $295 million based on the latest foreign currency exchange rates.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on GKOS:
- Glaukos announces clinical updates for several corneal disorders
- Glaukos announces positive results for iDose TR exchange trial
- Castle Biosciences, Academy Sports on Stephens ‘Best Ideas’ list for 2023
- Stephens carries over seven stocks to ‘Best Ideas’ list for 2023
- Glaukos price target lowered to $68 from $69 at Stephens